Volume 11, Number 3, March 2005

Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes

Nigel J. Temperton,* Paul K. Chan,† Graham Simmons,‡ Maria C. Zambon,§ Richard S. Tedder,* Yasuhiro Takeuchi,* and Robin A. Weiss*
*University College London, London, United Kingdom; †Prince of Wales Hospital, Shatin, New Territories, Hong Kong Special Administrative Region, People's Republic of China; ‡University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; and §Health Protection Agency Central Public Health Laboratory, London, United Kingdom

Figure 3. Severe acute respiratory syndrome–associated coronavirus (SARS-CoV) neutralizing antibody–positive rate by time of blood sample collection (days after onset of fever). Black bars represent the number of patients tested for neutralizing antibodies (Nab). White bars represent the number of patients whose assayed samples were positive for neutralizing antibodies (Nab+). Samples are considered positive for Nab if the 90% neutralizing antibody titer determined by using murine leukemia virus (MLV) (SARS) pseudotypes is >10. Line plot with open white circles shows the geometric mean (GM) Nab titer within each time frame. IC₉₀, 90% inhibitory concentration.

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed February 14, 2005

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention